B-intervention	0	7	Partial
I-intervention	7	8	-
I-intervention	8	14	breast
I-intervention	15	27	radiotherapy
O	28	33	after
O	34	40	breast
O	41	53	conservation
O	54	61	surgery
O	62	65	for
O	66	74	patients
O	75	79	with
O	80	85	early
O	86	92	breast
O	93	99	cancer
O	100	101	(
O	101	103	UK
O	104	110	IMPORT
O	111	114	LOW
O	115	120	trial
O	120	121	)
O	121	122	:
O	123	124	5
O	124	125	-
O	125	129	year
O	130	137	results
O	138	142	from
O	143	144	a
O	145	156	multicentre
O	156	157	,
O	158	168	randomised
O	168	169	,
O	170	180	controlled
O	180	181	,
O	182	187	phase
O	188	189	3
O	189	190	,
O	191	194	non
O	194	195	-
O	195	206	inferiority
O	207	212	trial
O	212	213	.

O	214	219	Local
O	220	226	cancer
O	227	234	relapse
O	235	239	risk
O	240	245	after
O	246	252	breast
O	253	265	conservation
O	266	273	surgery
O	274	282	followed
O	283	285	by
O	286	298	radiotherapy
O	299	302	has
O	303	309	fallen
O	310	317	sharply
O	318	320	in
O	321	325	many
O	326	335	countries
O	335	336	,
O	337	340	and
O	341	343	is
O	344	354	influenced
O	355	357	by
O	358	365	patient
O	366	369	age
O	370	373	and
O	374	393	clinicopathological
O	394	401	factors
O	401	402	.

O	403	405	We
O	406	417	hypothesise
O	418	422	that
O	423	430	partial
O	430	431	-
O	431	437	breast
O	438	450	radiotherapy
O	451	461	restricted
O	462	464	to
O	465	468	the
O	469	477	vicinity
O	478	480	of
O	481	484	the
O	485	493	original
O	494	500	tumour
O	501	503	in
O	504	509	women
O	510	512	at
O	513	518	lower
O	519	523	than
O	524	531	average
O	532	536	risk
O	537	539	of
O	540	545	local
O	546	553	relapse
O	554	558	will
O	559	566	improve
O	567	570	the
O	571	578	balance
O	579	581	of
O	582	592	beneficial
O	593	599	versus
O	600	607	adverse
O	608	615	effects
O	616	624	compared
O	625	629	with
O	630	635	whole
O	635	636	-
O	636	642	breast
O	643	655	radiotherapy
O	655	656	.

O	657	663	IMPORT
O	664	667	LOW
O	668	670	is
O	671	672	a
O	673	684	multicentre
O	684	685	,
O	686	696	randomised
O	696	697	,
O	698	708	controlled
O	708	709	,
O	710	715	phase
O	716	717	3
O	717	718	,
O	719	722	non
O	722	723	-
O	723	734	inferiority
O	735	740	trial
O	741	745	done
O	746	748	in
O	749	751	30
O	752	764	radiotherapy
O	765	772	centres
O	773	775	in
O	776	779	the
B-location	780	782	UK
O	782	783	.

O	784	789	Women
O	790	794	aged
B-age	795	797	50
I-age	798	803	years
I-age	804	806	or
I-age	807	812	older
B-eligibility	813	816	who
I-eligibility	817	820	had
I-eligibility	821	830	undergone
I-eligibility	831	837	breast
I-eligibility	837	838	-
I-eligibility	838	848	conserving
I-eligibility	849	856	surgery
I-eligibility	857	860	for
I-eligibility	861	869	unifocal
I-eligibility	870	878	invasive
I-eligibility	879	885	ductal
I-eligibility	886	900	adenocarcinoma
I-eligibility	901	903	of
I-eligibility	904	909	grade
I-eligibility	910	911	1
I-eligibility	911	912	-
I-eligibility	912	913	3
I-eligibility	913	914	,
I-eligibility	915	919	with
I-eligibility	920	921	a
I-eligibility	922	928	tumour
I-eligibility	929	933	size
I-eligibility	934	936	of
I-eligibility	937	938	3
I-eligibility	939	941	cm
I-eligibility	942	944	or
I-eligibility	945	949	less
I-eligibility	950	951	(
I-eligibility	951	954	pT1
I-eligibility	954	955	-
I-eligibility	955	956	2
I-eligibility	956	957	)
I-eligibility	957	958	,
I-eligibility	959	963	none
I-eligibility	964	966	to
I-eligibility	967	972	three
I-eligibility	973	981	positive
I-eligibility	982	990	axillary
I-eligibility	991	996	nodes
I-eligibility	997	998	(
I-eligibility	998	1001	pN0
I-eligibility	1001	1002	-
I-eligibility	1002	1003	1
I-eligibility	1003	1004	)
I-eligibility	1004	1005	,
I-eligibility	1006	1009	and
I-eligibility	1010	1017	minimum
I-eligibility	1018	1029	microscopic
I-eligibility	1030	1037	margins
I-eligibility	1038	1040	of
I-eligibility	1041	1044	non
I-eligibility	1044	1045	-
I-eligibility	1045	1054	cancerous
I-eligibility	1055	1061	tissue
I-eligibility	1062	1064	of
I-eligibility	1065	1066	2
I-eligibility	1067	1069	mm
I-eligibility	1070	1072	or
I-eligibility	1073	1077	more
O	1077	1078	,
O	1079	1083	were
O	1084	1093	recruited
O	1093	1094	.

O	1095	1103	Patients
O	1104	1108	were
O	1109	1117	randomly
O	1118	1126	assigned
O	1127	1128	(
O	1128	1129	1
O	1129	1130	:
O	1130	1131	1
O	1131	1132	:
O	1132	1133	1
O	1133	1134	)
O	1135	1137	to
O	1138	1145	receive
B-control	1146	1148	40
I-control	1149	1151	Gy
I-control	1152	1157	whole
I-control	1157	1158	-
I-control	1158	1164	breast
I-control	1165	1177	radiotherapy
I-control	1178	1179	(
I-control	1179	1186	control
I-control	1186	1187	)
O	1187	1188	,
O	1189	1191	36
O	1192	1194	Gy
O	1195	1200	whole
O	1200	1201	-
O	1201	1207	breast
O	1208	1220	radiotherapy
O	1221	1224	and
O	1225	1227	40
O	1228	1230	Gy
O	1231	1233	to
O	1234	1237	the
O	1238	1245	partial
O	1246	1252	breast
O	1253	1254	(
O	1254	1261	reduced
O	1261	1262	-
O	1262	1266	dose
O	1267	1272	group
O	1272	1273	)
O	1273	1274	,
O	1275	1277	or
O	1278	1280	40
O	1281	1283	Gy
O	1284	1286	to
O	1287	1290	the
O	1291	1298	partial
O	1299	1305	breast
O	1306	1310	only
O	1311	1312	(
O	1312	1319	partial
O	1319	1320	-
O	1320	1326	breast
O	1327	1332	group
O	1332	1333	)
O	1334	1336	in
O	1337	1339	15
O	1340	1345	daily
O	1346	1355	treatment
O	1356	1365	fractions
O	1365	1366	.

O	1367	1375	Computer
O	1375	1376	-
O	1376	1385	generated
O	1386	1392	random
O	1393	1401	permuted
O	1402	1408	blocks
O	1409	1410	(
O	1410	1415	mixed
O	1416	1421	sizes
O	1422	1424	of
O	1425	1428	six
O	1429	1432	and
O	1433	1437	nine
O	1437	1438	)
O	1439	1443	were
O	1444	1448	used
O	1449	1451	to
O	1452	1458	assign
O	1459	1467	patients
O	1468	1470	to
O	1471	1477	groups
O	1477	1478	,
O	1479	1490	stratifying
O	1491	1499	patients
O	1500	1502	by
O	1503	1515	radiotherapy
O	1516	1525	treatment
O	1526	1532	centre
O	1532	1533	.

O	1534	1542	Patients
O	1543	1546	and
O	1547	1557	clinicians
O	1558	1562	were
O	1563	1566	not
O	1567	1573	masked
O	1574	1576	to
O	1577	1586	treatment
O	1587	1597	allocation
O	1597	1598	.

O	1599	1604	Field
O	1604	1605	-
O	1605	1607	in
O	1607	1608	-
O	1608	1613	field
O	1614	1623	intensity
O	1623	1624	-
O	1624	1633	modulated
O	1634	1646	radiotherapy
O	1647	1650	was
O	1651	1660	delivered
O	1661	1666	using
O	1667	1675	standard
O	1676	1686	tangential
O	1687	1692	beams
O	1693	1697	that
O	1698	1702	were
O	1703	1709	simply
O	1710	1717	reduced
O	1718	1720	in
O	1721	1727	length
O	1728	1731	for
O	1732	1735	the
O	1736	1743	partial
O	1743	1744	-
O	1744	1750	breast
O	1751	1756	group
O	1756	1757	.

O	1758	1761	The
O	1762	1769	primary
O	1770	1778	endpoint
O	1779	1782	was
B-outcome-Measure	1783	1794	ipsilateral
I-outcome-Measure	1795	1800	local
I-outcome-Measure	1801	1808	relapse
O	1809	1810	(
O	1810	1812	80
O	1812	1813	%
O	1814	1819	power
O	1820	1822	to
O	1823	1830	exclude
O	1831	1832	a
O	1833	1834	2
O	1834	1835	·
O	1835	1836	5
O	1836	1837	%
O	1838	1846	increase
O	1847	1848	[
O	1848	1851	non
O	1851	1852	-
O	1852	1863	inferiority
O	1864	1870	margin
O	1870	1871	]
O	1872	1874	at
O	1875	1876	5
O	1877	1882	years
O	1883	1886	for
O	1887	1891	each
O	1892	1904	experimental
O	1905	1910	group
O	1910	1911	;
O	1912	1915	non
O	1915	1916	-
O	1916	1927	inferiority
O	1928	1931	was
O	1932	1937	shown
O	1938	1940	if
O	1941	1944	the
O	1945	1950	upper
O	1951	1956	limit
O	1957	1959	of
O	1960	1963	the
O	1964	1967	two
O	1967	1968	-
O	1968	1973	sided
O	1974	1976	95
O	1976	1977	%
O	1978	1980	CI
O	1981	1984	for
O	1985	1988	the
O	1989	1994	local
O	1995	2002	relapse
O	2003	2009	hazard
O	2010	2015	ratio
O	2016	2017	[
O	2017	2019	HR
O	2019	2020	]
O	2021	2024	was
O	2025	2029	less
O	2030	2034	than
O	2035	2036	2
O	2036	2037	·
O	2037	2039	03
O	2039	2040	)
O	2040	2041	,
O	2042	2050	analysed
O	2051	2053	by
O	2054	2063	intention
O	2064	2066	to
O	2067	2072	treat
O	2072	2073	.

O	2074	2080	Safety
O	2081	2089	analyses
O	2090	2094	were
O	2095	2099	done
O	2100	2102	in
O	2103	2106	all
O	2107	2115	patients
O	2116	2119	for
O	2120	2124	whom
O	2125	2129	data
O	2130	2133	was
O	2134	2143	available
O	2144	2145	(
O	2145	2147	ie
O	2147	2148	,
O	2149	2150	a
O	2151	2159	modified
O	2160	2169	intention
O	2169	2170	-
O	2170	2172	to
O	2172	2173	-
O	2173	2178	treat
O	2179	2189	population
O	2189	2190	)
O	2190	2191	.

O	2192	2196	This
O	2197	2202	study
O	2203	2205	is
O	2206	2216	registered
O	2217	2219	in
O	2220	2223	the
O	2224	2230	ISRCTN
O	2231	2239	registry
O	2239	2240	,
O	2241	2247	number
O	2248	2262	ISRCTN12852634
O	2262	2263	.

O	2264	2271	Between
O	2272	2275	May
O	2276	2277	3
O	2277	2278	,
O	2279	2283	2007
O	2283	2284	,
O	2285	2288	and
O	2289	2292	Oct
O	2293	2294	5
O	2294	2295	,
O	2296	2300	2010
O	2300	2301	,
B-total-participants	2302	2306	2018
O	2307	2312	women
O	2313	2317	were
O	2318	2327	recruited
O	2327	2328	.

O	2329	2332	Two
O	2333	2338	women
O	2339	2347	withdrew
O	2348	2355	consent
O	2356	2359	for
O	2360	2363	use
O	2364	2366	of
O	2367	2372	their
O	2373	2377	data
O	2378	2380	in
O	2381	2384	the
O	2385	2393	analysis
O	2393	2394	.

B-control-participants	2395	2398	674
O	2399	2407	patients
O	2408	2412	were
O	2413	2421	analysed
O	2422	2424	in
O	2425	2428	the
O	2429	2434	whole
O	2434	2435	-
O	2435	2441	breast
O	2442	2454	radiotherapy
O	2455	2456	(
O	2456	2463	control
O	2463	2464	)
O	2465	2470	group
O	2470	2471	,
B-intervention-participants	2472	2475	673
O	2476	2478	in
O	2479	2482	the
O	2483	2490	reduced
O	2490	2491	-
O	2491	2495	dose
O	2496	2501	group
O	2501	2502	,
O	2503	2506	and
B-intervention-participants	2507	2510	669
O	2511	2513	in
O	2514	2517	the
O	2518	2525	partial
O	2525	2526	-
O	2526	2532	breast
O	2533	2538	group
O	2538	2539	.

O	2540	2546	Median
O	2547	2553	follow
O	2553	2554	-
O	2554	2556	up
O	2557	2560	was
O	2561	2563	72
O	2563	2564	·
O	2564	2565	2
O	2566	2572	months
O	2573	2574	(
O	2574	2577	IQR
O	2578	2580	61
O	2580	2581	·
O	2581	2582	7
O	2582	2583	-
O	2583	2585	83
O	2585	2586	·
O	2586	2587	2
O	2587	2588	)
O	2588	2589	,
O	2590	2593	and
O	2594	2595	5
O	2595	2596	-
O	2596	2600	year
O	2601	2610	estimates
O	2611	2613	of
B-outcome	2614	2619	local
I-outcome	2620	2627	relapse
I-outcome	2628	2638	cumulative
I-outcome	2639	2648	incidence
O	2649	2653	were
B-cv-bin-percent	2654	2655	1
I-cv-bin-percent	2655	2656	·
I-cv-bin-percent	2656	2657	1
I-cv-bin-percent	2657	2658	%
O	2659	2660	(
O	2660	2662	95
O	2662	2663	%
O	2664	2666	CI
O	2667	2668	0
O	2668	2669	·
O	2669	2670	5
O	2670	2671	-
O	2671	2672	2
O	2672	2673	·
O	2673	2674	3
O	2674	2675	)
O	2676	2678	of
O	2679	2687	patients
O	2688	2690	in
O	2691	2694	the
O	2695	2702	control
O	2703	2708	group
O	2708	2709	,
B-iv-bin-percent	2710	2711	0
I-iv-bin-percent	2711	2712	·
I-iv-bin-percent	2712	2713	2
I-iv-bin-percent	2713	2714	%
O	2715	2716	(
O	2716	2717	0
O	2717	2718	·
O	2718	2720	02
O	2720	2721	-
O	2721	2722	1
O	2722	2723	·
O	2723	2724	2
O	2724	2725	)
O	2726	2728	in
O	2729	2732	the
O	2733	2740	reduced
O	2740	2741	-
O	2741	2745	dose
O	2746	2751	group
O	2751	2752	,
O	2753	2756	and
B-iv-bin-percent	2757	2758	0
I-iv-bin-percent	2758	2759	·
I-iv-bin-percent	2759	2760	5
I-iv-bin-percent	2760	2761	%
O	2762	2763	(
O	2763	2764	0
O	2764	2765	·
O	2765	2766	2
O	2766	2767	-
O	2767	2768	1
O	2768	2769	·
O	2769	2770	4
O	2770	2771	)
O	2772	2774	in
O	2775	2778	the
O	2779	2786	partial
O	2786	2787	-
O	2787	2793	breast
O	2794	2799	group
O	2799	2800	.

O	2801	2810	Estimated
O	2811	2812	5
O	2812	2813	-
O	2813	2817	year
O	2818	2826	absolute
O	2827	2838	differences
O	2839	2841	in
B-outcome	2842	2847	local
I-outcome	2848	2855	relapse
O	2856	2864	compared
O	2865	2869	with
O	2870	2873	the
O	2874	2881	control
O	2882	2887	group
O	2888	2892	were
O	2893	2894	-
O	2894	2895	0
O	2895	2896	·
O	2896	2898	73
O	2898	2899	%
O	2900	2901	(
O	2901	2902	-
O	2902	2903	0
O	2903	2904	·
O	2904	2906	99
O	2907	2909	to
O	2910	2911	0
O	2911	2912	·
O	2912	2914	22
O	2914	2915	)
O	2916	2919	for
O	2920	2923	the
O	2924	2931	reduced
O	2931	2932	-
O	2932	2936	dose
O	2937	2940	and
O	2941	2942	-
O	2942	2943	0
O	2943	2944	·
O	2944	2946	38
O	2946	2947	%
O	2948	2949	(
O	2949	2950	-
O	2950	2951	0
O	2951	2952	·
O	2952	2954	84
O	2955	2957	to
O	2958	2959	0
O	2959	2960	·
O	2960	2962	90
O	2962	2963	)
O	2964	2967	for
O	2968	2971	the
O	2972	2979	partial
O	2979	2980	-
O	2980	2986	breast
O	2987	2993	groups
O	2993	2994	.

O	2995	2998	Non
O	2998	2999	-
O	2999	3010	inferiority
O	3011	3014	can
O	3015	3017	be
O	3018	3025	claimed
O	3026	3029	for
O	3030	3034	both
O	3035	3042	reduced
O	3042	3043	-
O	3043	3047	dose
O	3048	3051	and
O	3052	3059	partial
O	3059	3060	-
O	3060	3066	breast
O	3067	3079	radiotherapy
O	3079	3080	,
O	3081	3084	and
O	3085	3088	was
O	3089	3098	confirmed
O	3099	3101	by
O	3102	3105	the
O	3106	3110	test
O	3111	3118	against
O	3119	3122	the
O	3123	3131	critical
O	3132	3134	HR
O	3135	3140	being
O	3141	3145	more
O	3146	3150	than
O	3151	3152	2
O	3152	3153	·
O	3153	3155	03
O	3156	3157	(
O	3157	3158	p
O	3158	3159	=
O	3159	3160	0
O	3160	3161	·
O	3161	3164	003
O	3165	3168	for
O	3169	3172	the
O	3173	3180	reduced
O	3180	3181	-
O	3181	3185	dose
O	3186	3191	group
O	3192	3195	and
O	3196	3197	p
O	3197	3198	=
O	3198	3199	0
O	3199	3200	·
O	3200	3203	016
O	3204	3207	for
O	3208	3211	the
O	3212	3219	partial
O	3219	3220	-
O	3220	3226	breast
O	3227	3232	group
O	3232	3233	,
O	3234	3242	compared
O	3243	3247	with
O	3248	3251	the
O	3252	3257	whole
O	3257	3258	-
O	3258	3264	breast
O	3265	3277	radiotherapy
O	3278	3283	group
O	3283	3284	)
O	3284	3285	.

O	3286	3298	Photographic
O	3298	3299	,
O	3300	3307	patient
O	3307	3308	,
O	3309	3312	and
O	3313	3321	clinical
O	3322	3333	assessments
O	3334	3342	recorded
O	3343	3350	similar
B-outcome	3351	3358	adverse
I-outcome	3359	3366	effects
O	3367	3372	after
O	3373	3380	reduced
O	3380	3381	-
O	3381	3385	dose
O	3386	3388	or
O	3389	3396	partial
O	3396	3397	-
O	3397	3403	breast
O	3404	3416	radiotherapy
O	3416	3417	,
O	3418	3427	including
O	3428	3431	two
O	3432	3439	patient
O	3440	3447	domains
O	3448	3457	achieving
O	3458	3471	statistically
O	3472	3485	significantly
O	3486	3491	lower
O	3492	3499	adverse
O	3500	3507	effects
O	3508	3509	(
B-outcome	3509	3515	change
I-outcome	3516	3518	in
I-outcome	3519	3525	breast
I-outcome	3526	3536	appearance
O	3537	3538	[
O	3538	3539	p
O	3539	3540	=
O	3540	3541	0
O	3541	3542	·
O	3542	3545	007
O	3546	3549	for
O	3550	3557	partial
O	3557	3558	-
O	3558	3564	breast
O	3564	3565	]
O	3566	3569	and
B-outcome	3570	3576	breast
I-outcome	3577	3583	harder
I-outcome	3584	3586	or
I-outcome	3587	3593	firmer
O	3594	3595	[
O	3595	3596	p
O	3596	3597	=
O	3597	3598	0
O	3598	3599	·
O	3599	3602	002
O	3603	3606	for
O	3607	3614	reduced
O	3614	3615	-
O	3615	3619	dose
O	3620	3623	and
O	3624	3625	p
O	3625	3626	<
O	3626	3627	0
O	3627	3628	·
O	3628	3632	0001
O	3633	3636	for
O	3637	3644	partial
O	3644	3645	-
O	3645	3651	breast
O	3651	3652	]
O	3652	3653	)
O	3654	3662	compared
O	3663	3667	with
O	3668	3673	whole
O	3673	3674	-
O	3674	3680	breast
O	3681	3693	radiotherapy
O	3693	3694	.

O	3695	3697	We
O	3698	3704	showed
O	3705	3708	non
O	3708	3709	-
O	3709	3720	inferiority
O	3721	3723	of
O	3724	3731	partial
O	3731	3732	-
O	3732	3738	breast
O	3739	3742	and
O	3743	3750	reduced
O	3750	3751	-
O	3751	3755	dose
O	3756	3768	radiotherapy
O	3769	3777	compared
O	3778	3782	with
O	3783	3786	the
O	3787	3795	standard
O	3796	3801	whole
O	3801	3802	-
O	3802	3808	breast
O	3809	3821	radiotherapy
O	3822	3824	in
O	3825	3830	terms
O	3831	3833	of
B-outcome	3834	3839	local
I-outcome	3840	3847	relapse
O	3848	3850	in
O	3851	3852	a
O	3853	3859	cohort
O	3860	3862	of
O	3863	3871	patients
O	3872	3876	with
O	3877	3882	early
O	3883	3889	breast
O	3890	3896	cancer
O	3896	3897	,
O	3898	3901	and
O	3902	3912	equivalent
O	3913	3915	or
O	3916	3921	fewer
O	3922	3926	late
O	3927	3933	normal
O	3933	3934	-
O	3934	3940	tissue
O	3941	3948	adverse
O	3949	3956	effects
O	3957	3961	were
O	3962	3966	seen
O	3966	3967	.

O	3968	3972	This
O	3973	3979	simple
O	3980	3992	radiotherapy
O	3993	4002	technique
O	4003	4005	is
O	4006	4019	implementable
O	4020	4022	in
O	4023	4035	radiotherapy
O	4036	4043	centres
O	4044	4053	worldwide
O	4053	4054	.

O	4055	4061	Cancer
O	4062	4070	Research
O	4071	4073	UK
O	4073	4074	.
